Across TCGA pan-cancer cohorts, INSIG2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated INSIG2 data layer compared with 26 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher INSIG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated INSIG2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.
GBM and LSCC are the cancer types where INSIG2 mass-spec protein most reproducibly stratifies survival.